Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 309-811-7 | CAS number: 101033-44-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Effect on fertility: via oral route
- Endpoint conclusion:
- no study available
- Study duration:
- chronic
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Effects on developmental toxicity
Description of key information
No studies were conducted on the target substance, Tetrakis [[2,2',2"-nitrilotris[ethanolato]](1-)-N,O]zirconium. As the target substance hydrolyses rapidly (half-life < 30 minutes) the intrinsic properties are related to hydrolysis products of the target substance, triethanolamine (TEA).
There were no studies available on fertility although there were no abnormalities noted in the histopathological examination of reproductive organs (testes and ovaries) in the 90-day oral and dermal toxicity studies. There was no evidence of developmental toxicity in the offspring of pregnant rats and mice (exposed during the major period of organogenesis to up to 30 mg/kg/day, and to 1125 mg/kg/day respectively using the oral route). (OECD SIDS 1995)
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Justification for type of information:
- triethanolamine is the main hydrolysis prodcuts of the target substance. Properties of the the hydrolysis substance are used for read-across.
- Qualifier:
- according to guideline
- Guideline:
- other: Chernoff-Kavlok teratogenicity screening test
- Principles of method if other than guideline:
- Post Natal Screening test - (Chernoff and Kavlock, 1982, 1983) The screen consisted of three experimental phases.
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- mouse
- Strain:
- CD-1
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- The daily dosing solutions were prepared and color coded by the chemistry staff at study initiation and were stored refrigerated in amber glass vials to prevent photodegradation. All dosing concentrations were verified as accurate by the chemistry staff. The animal technicians dosing the animals were not aware of the test article name and were blind to doses. Each test article was identified by the number assigned by the Radian Corp. and a corresponding color. This technique allowed for unbiased clinical observations.
- Analytical verification of doses or concentrations:
- yes
- Details on mating procedure:
- not specified.
- Duration of treatment / exposure:
- on days 6-15 of gestation
- Frequency of treatment:
- daily
- Duration of test:
- until post partum day 3
- Dose / conc.:
- 1 125 mg/kg bw/day
- Remarks:
- Phase III
- No. of animals per sex per dose:
- 3 virgin females (Phase I)
2-4 mated females (Phase II)
50 mated females (Phase III) - Control animals:
- yes, concurrent vehicle
- Details on study design:
- Sex: female
Duration of test: up to 3 days post partum - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 1 125 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 1 125 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Key result
- Abnormalities:
- no effects observed
- Remarks on result:
- not measured/tested
- Abnormalities:
- not specified
- Developmental effects observed:
- not specified
- Conclusions:
- Oral administration of 1125 mg/kg/day triethanolamine to pregnant mice did not affect maternal mortality, the number of viable litters, litter size, percent survival or pups, or birth weight or weight gained by the pups. No further details of study available.
- Executive summary:
As the target substance hydrolyses rapidly (half-life < 30 minutes) the intrinsic properties are related to hydrolysis products of the target substance. This information is used as a supporting evidence on the toxicity of the target substance in CSA.
- Endpoint:
- developmental toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Justification for type of information:
- triethanolamine is the main hydrolysis prodcuts of the target substance. Properties of the the hydrolysis substance are used for read-across.
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- other: Chernoff-Kavlok teratogenicity screening test
- Principles of method if other than guideline:
- Post Natal Screening test - (Chernoff and Kavlock, 1982, 1983) The screen consisted of three experimental phases.
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- mouse
- Strain:
- CD-1
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- The daily dosing solutions were prepared and color coded by the chemistry staff at study initiation and were stored refrigerated in amber glass vials to prevent photodegradation. All dosing concentrations were verified as accurate by the chemistry staff. The animal technicians dosing the animals were not aware of the test article name and were blind to doses. Each test article was identified by the number assigned by the Radian Corp. and a corresponding color. This technique allowed for unbiased clinical observations.
- Analytical verification of doses or concentrations:
- yes
- Details on mating procedure:
- not specified.
- Duration of treatment / exposure:
- on days 6-15 of gestation
- Frequency of treatment:
- daily
- Duration of test:
- until post partum day 3
- Dose / conc.:
- 1 125 mg/kg bw/day
- Remarks:
- Phase III
- No. of animals per sex per dose:
- 3 virgin females (Phase I)
2-4 mated females (Phase II)
50 mated females (Phase III) - Control animals:
- yes, concurrent vehicle
- Details on study design:
- Sex: female
Duration of test: up to 3 days post partum - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 1 125 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 1 125 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Key result
- Abnormalities:
- no effects observed
- Remarks on result:
- not measured/tested
- Abnormalities:
- not specified
- Developmental effects observed:
- not specified
- Conclusions:
- Oral administration of 1125 mg/kg/day triethanolamine to pregnant mice did not affect maternal mortality, the number of viable litters, litter size, percent survival or pups, or birth weight or weight gained by the pups. No further details of study available.
- Executive summary:
The study was conducted on triethanolamine, the strucural analogue and also the hydrolysis product of the target substance. As the target substance is hydrolytically unstable, its intrinsic property lies in the the hydrolysis products. The result is used as weight of evidence approach in hazard assessment.
Referenceopen allclose all
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 125 mg/kg bw/day
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the studies, there's no adverse effect on reproduction observed. Therefore, there is no need for classification as reproductive toxicity according to CLP Regulation.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.